Published time: 03 June 2020
Authors: David R. Boulware, Matthew F. Pullen, Ananta S. Bangdiwala, Katelyn A. Pastick, Sarah M. Lofgren, Elizabeth C. Okafor, Caleb P. Skipper, Alanna A. Nascene, Melanie R. Nicol, Pharm.D., Mahsa Abassi, Nicole W. Engen, Matthew P. Cheng
Keywords: Infectious Disease, Viral Infections, Influenza, Global Health
Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine. Whether hydroxychloroquine can prevent symptomatic infection after SARS-CoV-2 exposure is unknown.
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19